Endo Plans Valstar Relaunch In Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
Bladder cancer drug, pulled from the market in 2002, became part of Endo’s portfolio when it acquired Indevus.
You may also be interested in...
Endo Reinforces Commitment To Pain With Novel Phase II Drug License
Endo licenses axomadol for chronic pain and diabetic neuropathic pain from Grunenthal; sNDA for Valstar in bladder cancer also approved.
Endo Branches Out With $370M Indevus Acquisition
Re-submission of Nebido NDA in the wings, sales force will target general practitioners with urology, endocrinology drugs to general practitioners.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.